NCT01278849View on ClinicalTrials.gov

An Open-label, Dose Escalation Study to Assess the Pharmacokinetics of of ASA404 in Adult Cancer Patients With Impaired Hepatic Function

PHASE1TerminatedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

January 31, 2010

Primary Completion Date

November 30, 2010

Conditions
Histologically-proven and Radiologically-confirmed Solid Tumors
Interventions
DRUG

ASA404

Trial Locations (4)

2104

Novartis Investigative Site, Milan

60126

Novartis Investigative Site, Ancona

Unknown

Novarts Investigative Site, Auckland

Novartis Investigative Site, Wellington

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY